Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABSTER phase II nab-paclitaxel in relapsed SCLC/LCNEC
2016-000408-27Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel in small cell lung cancer (SCLC), Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) and Lung neuroendocrine carcinoma (LNEC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Objective tumor response. Started Nov 2020; status: completed.
02
Drugs
paclitaxel
03
Conditions
small cell lung cancer (SCLC)Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)Lung neuroendocrine carcinoma (LNEC)
Beyond the preview
Go deeper on 2016-000408-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000408-27.